Phase II data for SR Pharma's SRL172

SR Pharma (LSE:SPA) said that in a Phase II trial of its SRL172 in 60 patients with renal cancer who had had a kidney removed, patients given monthly injections of SRL172 had significantly longer survival times than historical values for patients treated with chemotherapy (p=0.001) but not patients treated with biologics (interleukin-2 or interferon-alpha). Patients receiving SRL172, a heat killed suspension of Mycobacterium vaccae, had an average survival time of 403 days compared to historical survival times of 368 days and 218 days for biological therapy and chemotherapy patients, respectively. SPA noted that the U.K. and French single arm trial did not prospectively randomize the patients. ...